Cardiac Evaluation, Toxicity and Monitoring in the Treatment of Breast Cancer

Seminars in Breast Disease

Volumn 9, Issue 4, 2006, Pages 160-167

  Stinis, Curtiss T ^a   Movahed, Mohammad Reza ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

breast cancer; cardiotoxicity; chemotherapy; MUGA; radionuclide angiocardiography

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; MITOXANTRONE; PACLITAXEL; RAZOXANE; TRASTUZUMAB;

ANGIOCARDIOGRAPHY; ARTICLE; BRADYCARDIA; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; RADIATION EXPOSURE; REPRODUCIBILITY; RISK REDUCTION; SIDE EFFECT;

EID: 34247186444     PISSN: 10924450     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sembd.2007.02.006     Document Type: Article

References (97)

1. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
2. AHA: Women, heart disease and stroke. Available at: http://www.americanheart.org
3. Ettinghausen S.E., Bonow R.O., Palmeri S.T., et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 121 (1986) 1445-1451
4. Bonadonna G., Zambetti M., and Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J Am Med Assoc 273 (1995) 542-547
5. Fisher B., Redmond C., Wickerham D.L., et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7 (1989) 572-582
6. Steinberg J.S., Cohen A.J., Wasserman A.G., et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 60 (1987) 1213-1218
7. Lenaz L.P.J. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3 (1976) 111-120
8. Ferrans V.J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62 (1978) 955-961
9. Von Hoff D.D., Rozencweig M., Layard M., et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62 (1977) 200-208
10. Bristow M.R., Billingham M.E., Mason J.W., et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62 (1978) 873-879
11. Praga C., Beretta G., Vigo P.L., et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63 (1979) 827-834
12. Steinherz L.J., Steinherz P.G., and Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24 (1995) 352-361
13. Steinherz L., and Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician 18 (1991) 49-52
14. Goorin A.M., Borow K.M., Goldman A., et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer 47 (1981) 2810-2816
15. Moreb J.S., and Oblon D.J. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 70 (1992) 2637-2641
16. Lewis A.B., Crouse V.L., Evans W., et al. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 68 (1981) 67-72
17. Haq M.M., Legha S.S., Choksi J., et al. Doxorubicin-induced congestive heart failure in adults. Cancer 56 (1985) 1361-1365
18. Steinherz L.J., Steinherz P.G., Tan C.T., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 266 (1991) 1672-1677
19. Larsen R.L., Jakacki R.I., Vetter V.L., et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70 (1992) 73-77
20. Bu'Lock F.A., Martin R.P., and Mott M.G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 24 (1995) 143-144
21. Ito H., Miller S.C., Billingham M.E., et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87 (1990) 4275-4279
22. Doroshow J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43 (1983) 460-472
23. Rajagopalan S., Politi P.M., Sinha B.K., et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48 (1988) 4766-4769
24. Jackson J.A., Reeves J.P., Muntz K.H., et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 117 (1984) 140-153
25. Singal P.K., and Pierce G.N. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250 (1986) H419-H425
26. Wakasugi S., Wada A., Hasegawa Y., et al. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 33 (1992) 208-214
27. Bristow M.R., Minobe W.A., Billingham M.E., et al. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest 45 (1981) 157-168
28. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72 (1994) 561-566
29. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
30. Leandro J., Dyck J., Poppe D., et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74 (1994) 1152-1156
31. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
32. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
33. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
34. Kremer L.C., and Caron H.N. Anthracycline cardiotoxicity in children. N Engl J Med 351 (2004) 120-121
35. Nysom K., Holm K., Lipsitz S.R., et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 16 (1998) 545-550
36. Legha S.S., Benjamin R.S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 (1982) 133-139
37. Kaklamani V.G., and Gradishar W.J. Epirubicin versus Doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?. Clin Breast Cancer 4 suppl 1 (2003) S26-S33
38. Young A.M., Dhillon T., and Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 5 (2004) 654
39. Gabizon A.A., Lyass O., Berry G.J., et al. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22 (2004) 663-669
40. Berry G., Billingham M., Alderman E., et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9 (1998) 711-716
41. 2. Ann Oncol 11 (2000) 1029-1033
42. van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev CD003917 (2005)
43. Akhtar S.S., Salim K.P., and Bano Z.A. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50 (1993) 441-444
44. Anand A.J. Fluorouracil cardiotoxicity. Ann Pharmacother 28 (1994) 374-378
45. Saif M., Szabo E., Grem J., et al. The clinical syndrome of 5-fluorouracil cardiotoxicity. (abstract). Proc Am Soc Clin Oncol 20 (2001) 404a
46. Kuropkat C., Griem K., Clark J., et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 22 (1999) 466-470
47. Cwikiel M., Eskilsson J., Wieslander J.B., et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 10 (1996) 805-818
48. Sasson Z., Morgan C.D., Wang B., et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10 (1994) 861-864
49. de Forni M., Malet-Martino M.C., Jaillais P., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10 (1992) 1795-1801
50. Labianca R., Beretta G., Clerici M., et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 68 (1982) 505-510
51. Wacker A., Lersch C., Scherpinski U., et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 65 (2003) 108-112
52. Oleksowicz L., and Bruckner H.W. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 85 (1988) 750-751
53. Kleiman N.S., Lehane D.E., Geyer Jr. C.E., et al. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med 82 (1987) 566-568
54. Rowinsky E.K., McGuire W.P., Guarnieri T., et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 9 (1991) 1704-1712
55. Rahman Z., Champlin R., Rondon G., et al. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24 (1997) S17-77-S17-80
56. Gianni L., Munzone E., Capri G., et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13 (1995) 2688-2699
57. Gehl J., Boesgaard M., Paaske T., et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7 (1996) 687-693
58. Lichtman S.M., Ratain M.J., Van Echo D.A., et al. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst 85 (1993) 1319-1326
59. Nieto Y., Cagnoni P.J., Bearman S.I., et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 6 (2000) 198-203
60. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 95 (2002) 1592-1600
61. Perez E.A., and Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22 (2004) 322-329
62. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
63. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
64. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
65. Feldman A.M., Lorell B.H., and Reis S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102 (2000) 272-274
66. Grote T.H., Pineda L.F., Figlin R.A., et al., Oral Dolasetron Dose Response Study Group. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am 3 (1997) 45-51
67. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
68. Erickson S.L., O'Shea K.S., Ghaboosi N., et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124 (1997) 4999-5011
69. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 (2002) 459-465
70. Klein P.M., and Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30 (2003) 49-53
71. Gaya A.M., and Ashford R.F. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol) 17 (2005) 153-159
72. Lee P.J., and Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev 13 (2005) 80-86
73. Daitoku K., Fukui K., Ichinoseki I., et al. Radiotherapy-induced aortic valve disease associated with porcelain aorta. Jpn J Thorac Cardiovasc Surg 52 (2004) 349-352
74. Adams M.J., Hardenbergh P.H., Constine L.S., et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45 (2003) 55-75
75. Billingham M.E., and Bristow M.R. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 3 (1984) 71-76
76. Mason J.W., Bristow M.R., Billingham M.E., et al. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62 (1978) 857-864
77. Isner J.M., Ferrans V.J., Cohen S.R., et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 51 (1983) 1167-1174
78. Alexander J., Dainiak N., Berger H.J., et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300 (1979) 278-283
79. Bristow M.R., Mason J.W., Billingham M.E., et al. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102 (1981) 709-718
80. McKillop J.H., Bristow M.R., Goris M.L., et al. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106 (1983) 1048-1056
81. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23 (2005) 2629-2636
82. Steinherz L.J., Graham T., Hurwitz R., et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89 (1992) 942-949
83. Stoddard M.F., Seeger J., Liddell N.E., et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20 (1992) 62-69
84. Cheitlin M.D., Alpert J.S., Armstrong W.F., et al. ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol 29 (1997) 862-879
85. Cheitlin M.D., Armstrong W.F., Aurigemma G.P., et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108 (2003) 1146-1162
86. Marchandise B., Schroeder E., Bosly A., et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118 (1989) 92-98
87. Lee B.H., Goodenday L.S., Muswick G.J., et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9 (1987) 184-188
88. Schmitt K., Tulzer G., Merl M., et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr 154 (1995) 201-204
89. Mortensen S.A., Olsen H.S., and Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 55 (1986) 274-282
90. Cottin Y., Touzery C., Coudert B., et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 73 (1995) 61-64
91. Schwartz R.G., McKenzie W.B., Alexander J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 (1987) 1109-1118
92. Herman E.H., Zhang J., Lipshultz S.E., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17 (1999) 2237-2243
93. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36 (2000) 517-522
94. Klewer S.E., Goldberg S.J., Donnerstein R.L., et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 19 (1992) 394-401
95. Weesner K.M., Bledsoe M., Chauvenet A., et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 68 (1991) 435-438
96. Gottdiener J.S., Mathisen D.J., Borer J.S., et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94 (1981) 430-435
97. Yeung S.T., Yoong C., Spink J., et al. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 337 (1991) 816-818